Eiger BioPharmaceuticals Investor Relations Material

Latest events

Status Update

Eiger BioPharmaceuticals

Q3 2023

9 Nov, 2023

Q2 2023

14 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Eiger BioPharmaceuticals Inc

Access all reports
Eiger BioPharmaceuticals, Inc. (EIGR), a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Eiger's most advanced pipeline product candidate is Zileuton XL, which is an oral prodrug of zileuton that is being developed for the treatment of eosinophilic airway diseases (EAD).